Eisai (OTCMKTS:ESALY) vs. SCHRODERS/PAR VTG FPD 1 (OTCMKTS:SHNWF) Head to Head Survey

Eisai (OTCMKTS:ESALY) and SCHRODERS/PAR VTG FPD 1 (OTCMKTS:SHNWF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Profitability

This table compares Eisai and SCHRODERS/PAR VTG FPD 1’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eisai 10.19% 10.23% 6.08%
SCHRODERS/PAR VTG FPD 1 N/A N/A N/A

Valuation and Earnings

This table compares Eisai and SCHRODERS/PAR VTG FPD 1’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eisai $5.42 billion N/A $466.60 million $1.63 35.50
SCHRODERS/PAR VTG FPD 1 $3.24 billion 3.26 N/A N/A N/A

Eisai has higher revenue and earnings than SCHRODERS/PAR VTG FPD 1.

Dividends

Eisai pays an annual dividend of $1.22 per share and has a dividend yield of 2.1%. SCHRODERS/PAR VTG FPD 1 does not pay a dividend. Eisai pays out 74.8% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Eisai and SCHRODERS/PAR VTG FPD 1, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eisai 3 0 0 0 1.00
SCHRODERS/PAR VTG FPD 1 0 2 0 0 2.00

Volatility and Risk

Eisai has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, SCHRODERS/PAR VTG FPD 1 has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Summary

Eisai beats SCHRODERS/PAR VTG FPD 1 on 5 of the 8 factors compared between the two stocks.

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and with Ono Pharmaceutical Co., Ltd. for Lenvima and Opdivo combination therapy for the treatment of hepatocellular carcinoma, as well as Collaboration Agreement with Ono Pharmaceutical Co., Ltd. to develop a therapy for treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

About SCHRODERS/PAR VTG FPD 1

Schroders plc is a publicly owned investment manager. The firm also provides advisory and consultancy services. It provides its services to financial institutions, high net worth clients, large corporate, local authority, charitable entities, individuals, pension plans, government funds, insurance companies, and endowments. It launches and manages equity mutual funds and manages fixed income mutual funds for its clients. The firm also manages hedge for its clients. It invests in the public equity, fixed income, and alternative investment markets across the globe. The firm's alternative investments include real estate markets, emerging market debt, commodities and agriculture funds, funds of hedge funds and private equity funds of funds. It conducts an in-house research to make its investments. Schroders plc was founded on 1804 and is headquartered in London, United Kingdom.

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.